The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
To investigate whether saxagliptin could reduce the fluctuation of glycemia and improve the
glycemic control in those type 1 diabetes through mechanisms of suppressing glucagon
secretion, improving beta cell function, and re-regulating of the T cell immune system.
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing Medical University
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Insulin Insulin, Globin Zinc Saxagliptin